# OnCo record turnstone-biologics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/turnstone-biologics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "turnstone-biologics" ;
  schema:name "Turnstone Biologics"@en ;
  schema:description "Turnstone developed 'selected' tumour-infiltrating lymphocyte therapy, enriching the most cancer-reactive immune cells from a patient's tumour. It stopped its clinical programme in January 2025 and was bought by XOMA Royalty later that year."@en ;
  schema:url <https://onco.cc/companies/turnstone-biologics/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.sec.gov/edgar/browse/?CIK=0001764974>, <https://www.sec.gov/Archives/edgar/data/1764974/000119312525151306/d928306dex991.htm>, <https://www.sec.gov/Archives/edgar/data/1764974/000119312525177597/d27108d8k.htm>, <https://www.sec.gov/Archives/edgar/data/1764974/000095017025047107/tsbx-ex99_1.htm>, <https://www.sec.gov/edgar/browse/?CIK=0001764974> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/til-therapy/> .